- Home
- CNTB vs SLS Comparison
CNTB vs SLS Comparison
Compare CNTB & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- SLS
- Stock Information
- Founded
- CNTB 2012
- SLS 2012
- Country
- CNTB United States
- SLS United States
- Employees
- CNTB N/A
- SLS N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- CNTB Health Care
- SLS Health Care
- Exchange
- CNTB Nasdaq
- SLS Nasdaq
- Market Cap
- CNTB 65.5M
- SLS 75.3M
- IPO Year
- CNTB 2021
- SLS N/A
- Fundamental
- Price
- CNTB $1.06
- SLS $0.88
- Analyst Decision
- CNTB Strong Buy
- SLS
- Analyst Count
- CNTB 1
- SLS 0
- Target Price
- CNTB $8.00
- SLS N/A
- AVG Volume (30 Days)
- CNTB 31.2K
- SLS 1.6M
- Earning Date
- CNTB 09-05-2024
- SLS 11-13-2024
- Dividend Yield
- CNTB N/A
- SLS N/A
- EPS Growth
- CNTB N/A
- SLS N/A
- EPS
- CNTB N/A
- SLS N/A
- Revenue
- CNTB $24,116,000.00
- SLS N/A
- Revenue This Year
- CNTB N/A
- SLS N/A
- Revenue Next Year
- CNTB $63.90
- SLS N/A
- P/E Ratio
- CNTB N/A
- SLS N/A
- Revenue Growth
- CNTB N/A
- SLS N/A
- 52 Week Low
- CNTB $0.77
- SLS $0.50
- 52 Week High
- CNTB $2.66
- SLS $1.72
- Technical
- Relative Strength Index (RSI)
- CNTB 46.58
- SLS 30.01
- Support Level
- CNTB $1.04
- SLS $0.86
- Resistance Level
- CNTB $1.23
- SLS $0.98
- Average True Range (ATR)
- CNTB 0.10
- SLS 0.11
- MACD
- CNTB 0.01
- SLS -0.02
- Stochastic Oscillator
- CNTB 42.37
- SLS 21.74
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.